Faculty of Medical Sciences in Katowice, Medical University of Silesia, Katowice, Poland.
1st Department of Cardiology, Medical University of Warsaw, Poland.
Cardiol J. 2023;30(1):131-142. doi: 10.5603/CJ.a2021.0006. Epub 2021 Jan 20.
Angiopoietin-like proteins (ANGPTL) are involved in the regulation of numerous physiological and biochemical processes. ANGPTL3, 4 and 8, which are involved in the regulation of lipoprotein metabolism, are particularly important. ANGPTL3, 4 and 8 have been shown to regulate triglyceride availability depending on the nutritional status of the body. In addition, a deficiency of these proteins has been found to cause hypolipidemia (reduction of all lipid fractions). Increases in ANGPTL3, 4 and 8 appear to be associated with cardiovascular risk. Animal studies indicate that the use of ANGPTL3 (evinacumab) inhibitors significantly reduces plasma total cholesterol, triglycerides and low-density lipoprotein concentrations. The use of evinacumab in clinical trials also led to the normalization of plasma lipid concentrations in patients with atherogenic dyslipidemia and homozygous familial hypercholesterolemia. The results of these studies indicate that evinacumab may in the future be used in the treatment of lipid disorders, especially those with hypertriglyceridemia.
血管生成素样蛋白 (ANGPTL) 参与多种生理和生化过程的调节。参与脂蛋白代谢调节的 ANGPTL3、4 和 8 尤为重要。研究表明，ANGPTL3、4 和 8 根据机体的营养状况调节甘油三酯的可用性。此外，这些蛋白的缺乏会导致低脂血症（所有脂质成分减少）。ANGPTL3、4 和 8 的增加似乎与心血管风险相关。动物研究表明，使用 ANGPTL3（依维莫司）抑制剂可显著降低血浆总胆固醇、甘油三酯和低密度脂蛋白浓度。依维莫司在临床试验中的应用也导致动脉粥样硬化性血脂异常和家族性高胆固醇血症患者的血浆脂质浓度正常化。这些研究结果表明，依维莫司将来可能用于治疗脂质紊乱，特别是那些伴有高甘油三酯血症的患者。
